Allakos Inc. (ALLK): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALLK Stock Price Chart Interactive Chart >
ALLK Price/Volume Stats
|Current price||$5.07||52-week high||$8.73|
|Prev. close||$5.45||52-week low||$2.54|
|Day high||$5.45||Avg. volume||989,633|
|50-day MA||$6.63||Dividend yield||N/A|
|200-day MA||$5.62||Market Cap||434.41M|
Allakos Inc. (ALLK) Company Bio
Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. The company was founded in 2012 and is based in San Carlos, California.
Most Popular Stories View All
ALLK Latest News Stream
|Loading, please wait...|
ALLK Latest Social Stream
View Full ALLK Social Stream
Latest ALLK News From Around the Web
Below are the latest news stories about ALLAKOS INC that investors may wish to consider to help them evaluate ALLK as an investment opportunity.
Allakos jumps 22% after Q4 update amid bullish views from Piper Sandler
Why Allakos Stock Was Heating Up Today
Although Allakos reported a net loss of $43 million in the fourth quarter of 2022, investors were more concerned with the progress of the company's clinical pipeline. More specifically, Allakos reaffirmed today that it expects to report trial results from a pair of ongoing mid-stage studies for its lead compound, lirentelimab, in the second half of 2023. The monoclonal antibody is presently in a phase 2 trial as a treatment for atopic dermatitis and a phase 2b trial for chronic spontaneous urticaria (hives).
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company’s most advanced antibodies are lirentelimab (AK002) and AK006. Recent Allakos Events Initiated a Phase 2b randomized, double-blind, placebo-cont
Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value
How far off is Allakos Inc. ( NASDAQ:ALLK ) from its intrinsic value? Using the most recent financial data, we'll take...
Is Allakos (NASDAQ:ALLK) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
ALLK Price Returns
Loading social stream, please wait...